<DOC>
	<DOCNO>NCT01282697</DOCNO>
	<brief_summary>Therapeutic solution treat solid tumor resistant conventional treatment limit . Laboratory data animal ( pediatric tumor brain tumor , sarcoma neuroblastoma ) show combination irinotecan ( HIF1alpha inhibitor ) rapamycin ( mTOR inhibitor ) allow block development blood vessel tumor could , case , stop progression . This drug combination already test adult patient refractory tumor seem give encouraging result stabilization tumor . The dose toxicity irinotecan rapamycin know drug administer separately context different refractory tumor . RAPIRI phase I clinical trial whose principal objective determine maximum dose two molecule may administer assess safety new combination drug .</brief_summary>
	<brief_title>Clinical Trial Rapamycin Irinotecan Pediatric Patients With Refractory Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Age &gt; = 1 year old = &lt; 21 year old ; Refractory solid tumor , histologically proven diagnosis ( additional biopsy need perform purpose study ) ; Relapsed refractory solid tumor standard treatment phase II , IIIIV clinical trial treatment fail ; Karnofsky Lansky status &gt; = 70 % ; Life expectancy &gt; = 8 week ; No chemotherapy / radiotherapy within 4 week entry study ; Adequate biological parameter : Absolute neutrophil count &gt; = 1.0 x 109/L ; Platelet count &gt; = 100 x 109/L ; Hemoglobin &gt; = 8 mg/dL ; Total bilirubine = &lt; 1.5 ULN ; Transaminases = &lt; 2.5 ULN ( = &lt; 5 ULN case liver metastasis ) ; Creatinine clearance ( Cockroft ) &gt; = 70 mL/min/1.73 m2 ; Normal coagulation profile prothrombin &gt; = 70 % , TCA = &lt; 35 fibrinogen &gt; = 2 g/L ; Patients 1 3 previous therapeutic line eligible ; No current grade &gt; = 2 organ toxicity base NCICTCAE version 3.0 ; All patient reproductive potential must effective method birth control study ; Negative pregnancy test female indicate ; Informed write consent sign patient parent legal guardian ; Patient inform result prior medical consultation ; Patient social insurance . Patient constitutional anomaly coagulation and/or hemostasis ( type hemophilia , von Willebrand disease , congenital clot factor deficit , platelet disorder ) , expose increase risk bleeding ; Pretreatment mTOR inhibitor ; Other simultaneous malignancy ; Concurrent administration antitumour therapy ; Known hypersensitivity contraindication study drug ingredient ; Severe concomitant disease ( e.g . infection disease ) ; Patient unable medical followup ; Pregnancy and/or lactation ; Patient include another clinical drug trial ; Patient take drug interfere pharmacology rapamycin and/or irinotecan ( e.g . drug interfere CYP3A4 ) ; Patient judicial protection .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>